Skip to main content
Premium Trial:

Request an Annual Quote

Pionyr Immunotherapeutics, Abcam Exploring Potential CDx for Anti-TREM2 Therapy

NEW YORK – Pionyr Immunotherapeutics said on Tuesday that it is extending its collaboration with Abcam to explore the development of a companion diagnostic for PY314, Pionyr's investigational anti-TREM2 agent.

Under a commercial licensing agreement, Cambridge, UK-based Abcam will provide its reagents, diagnostics expertise, and its anti-TREM2 antibody, an EPR20243 clone, to help South San Francisco, California-based Pionyr identify patients who are enrolled in an ongoing Phase I trial of PY314 and have TREM2-expressing macrophages in tumor samples.

The first-in-human study is assessing the activity of PY314, designed to deplete immunosuppressive, TREM2-expressing macrophages, in patients with previously treated, advanced solid tumors including breast, lung, gastric, colon, kidney, and gynecologic cancers.

"Precise monitoring of the presence of TREM2 in tumor biopsy samples throughout the clinical development process, enabled by Pionyr's use of Abcam's EPR20243 clone, will provide vital support to the success of the trial," said John Baker, Abcam's senior VP of business development.